- Home
- HQH vs PHAR Comparison
HQH vs PHAR Comparison
Compare HQH & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HQH | PHAR |
|---|---|---|
| Founded | 1986 | 1988 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.1B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | HQH | PHAR |
|---|---|---|
| Price | $18.34 | $16.92 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $39.00 |
| AVG Volume (30 Days) | ★ 149.2K | 18.1K |
| Earning Date | 01-01-0001 | 03-12-2026 |
| Dividend Yield | ★ 11.56% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.09 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $10.04 |
| Revenue Next Year | N/A | $2.70 |
| P/E Ratio | ★ $16.39 | $3,041.22 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.77 | $7.50 |
| 52 Week High | $20.46 | $21.34 |
Technical Indicators
Market Signals| Indicator | HQH | PHAR |
|---|---|---|
| Relative Strength Index (RSI) | 49.70 | 58.38 |
| Support Level | $17.70 | $15.72 |
| Resistance Level | $19.57 | $17.60 |
| Average True Range (ATR) | 0.47 | 0.61 |
| MACD | 0.03 | 0.20 |
| Stochastic Oscillator | 67.47 | 94.68 |
Price Performance
Historical ComparisonAbout HQH abrdn Healthcare Investors Shares of Beneficial Interest
abrdn Healthcare Investors Formerly Tekla Healthcare Investors is the United States based non-diversified closed-end management investment company. Its objective is to seek long-term capital appreciation by investing in securities of healthcare companies. In addition, the fund seeks to provide regular distribution of realized capital gains. The fund invests in the securities of public and private companies.
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.